These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 35779750)
1. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas. Ma K; Chen S; Chen X; Yang C; Yang J World Neurosurg; 2022 Sep; 165():e650-e663. PubMed ID: 35779750 [TBL] [Abstract][Full Text] [Related]
2. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas. Ma K; Chen X; Liu W; Chen S; Yang C; Yang J Sci Rep; 2022 Mar; 12(1):4295. PubMed ID: 35277559 [TBL] [Abstract][Full Text] [Related]
3. CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance. Ma K; Chen S; Chen X; Zhao X; Yang J J Mol Neurosci; 2022 Oct; 72(10):2106-2124. PubMed ID: 36006582 [TBL] [Abstract][Full Text] [Related]
4. PLVAP is associated with glioma-associated malignant processes and immunosuppressive cell infiltration as a promising marker for prognosis. Ma K; Chen X; Zhao X; Chen S; Yang J Heliyon; 2022 Aug; 8(8):e10298. PubMed ID: 36033326 [TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444 [TBL] [Abstract][Full Text] [Related]
6. ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression. Ma K; Chen X; Liu W; Yang Y; Chen S; Sun J; Ma C; Wang T; Yang J Sci Rep; 2021 Oct; 11(1):20839. PubMed ID: 34675316 [TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094 [TBL] [Abstract][Full Text] [Related]
8. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
9. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866 [TBL] [Abstract][Full Text] [Related]
10. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas. Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161 [TBL] [Abstract][Full Text] [Related]
11. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
13. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617 [TBL] [Abstract][Full Text] [Related]
14. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples. Song Z; Wang Y; Du Y; Zhang Z; Yuan Y Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440 [TBL] [Abstract][Full Text] [Related]
15. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas. Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813 [TBL] [Abstract][Full Text] [Related]
16. DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas. Chang X; Pan J; Zhao R; Yan T; Wang X; Guo C; Yang Y; Wang G Front Immunol; 2022; 13():917014. PubMed ID: 35812432 [TBL] [Abstract][Full Text] [Related]
17. Transcriptome profile and clinical characterization of ICOS expression in gliomas. Wang J; Shi F; Shan A Front Oncol; 2022; 12():946967. PubMed ID: 36276141 [TBL] [Abstract][Full Text] [Related]
18. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489 [TBL] [Abstract][Full Text] [Related]
19. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139 [TBL] [Abstract][Full Text] [Related]
20. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma. Wang X; Yang Q; Liu N; Bian Q; Gao M; Hou X Pathol Oncol Res; 2021; 27():1609825. PubMed ID: 34629960 [No Abstract] [Full Text] [Related] [Next] [New Search]